April 23, 2025
The National Institute for Health and Care Excellence (NICE) has recommended nivolumab (Opdivo) plus ipilimumab (Yervoy) for some people in England with advanced colorectal cancer. The […]
April 18, 2025
The US Food and Drug Administration (FDA) has approved dupilumab for the treatment of chronic spontaneous urticaria (CSU) in patients aged 12 years and older who […]
April 18, 2025
The US Food and Drug Administration (FDA) has granted marketing authorization to CT-132 (Click Therapeutics), an adjunctive, first-in-class prescription digital therapeutic for the preventive treatment of […]
April 18, 2025
The US Food and Drug Administration (FDA) has approved a new indication for osilodrostat (Isturisa, Recordati) as second-line treatment of endogenous hypercortisolemia in adults with Cushing […]
April 14, 2025
The U.S. Food and Drug Administration (FDA) and Novo Nordisk are warning people not to use counterfeit semaglutide 1.0 mg (Ozempic injection) found in the US […]
April 14, 2025
The US Food and Drug Administration (FDA) has approved a prefilled syringe for self-injection of efgartigimod alfa and hyaluronidase-qvfc (Vyvgart Hytrulo, argenx) in the treatment of […]
April 11, 2025
The National Institute for Health and Care Excellence (NICE) has recommended a new twice-daily tablet for some patients in England with locally advanced or metastatic breast […]
April 10, 2025
The Dexcom G7 continuous glucose monitor (CGM) will now last 15 days, up from the previous 10-day version. The US Food and Drug Administration’s clearance of […]
April 10, 2025
The National Institute for Health and Care Excellence (NICE) has recommended erdafitinib (Balversa, Johnson & Johnson) as a treatment option for adults with unresectable or metastatic […]